Proteon logo     Print Page | Close Window

SEC Filings

10-Q
PROTEON THERAPEUTICS INC filed this Form 10-Q on 08/07/2017
Entire Document
 
 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ]   No [X]

 

As of July 31, 2017 there were 17,619,418 shares of the registrant’s common stock, par value $0.001 per share, outstanding.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 2